TY - JOUR
T1 - Molecular profiling of cancer - The future of personalized cancer medicine
T2 - A primer on cancer biology and the tools necessary to bring molecular testing to the clinic
AU - Stricker, Thomas
AU - Catenacci, Daniel V.T.
AU - Seiwert, Tanguy Y.
N1 - Funding Information:
Grant Support: Flight Attendant Medical Research Institute (FAMRI) Young Investigator Award (T.Y.S.). ASCO translational research professorship (T.Y.S. /PI:.Everett Vokes). Cancer Research Foundation Young Investigator Award (T.Y.S.). ASCO Young Investigator Award (D.V.T.C.). Amgen Oncology Fellowship Award (D.V.T.C.).
Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2011/4
Y1 - 2011/4
N2 - Cancers arise as a result of an accumulation of genetic aberrations that are either acquired or inborn. Virtually every cancer has its unique set of molecular changes. Technologies have been developed to study cancers and derive molecular characteristics that increasingly have implications for clinical care. Indeed, the identification of key genetic aberrations (molecular drivers) may ultimately translate into dramatic benefit for patients through the development of highly targeted therapies. With the increasing availability of newer, more powerful, and cheaper technologies such as multiplex mutational screening, next generation sequencing, array-based approaches that can determine gene copy numbers, methylation, expression, and others, as well as more sophisticated interpretation of high-throughput molecular information using bioinformatics tools like signatures and predictive algorithms, cancers will routinely be characterized in the near future. This review examines the background information and technologies that clinicians and physicianscientists will need to interpret in order to develop better, personalized treatment strategies.
AB - Cancers arise as a result of an accumulation of genetic aberrations that are either acquired or inborn. Virtually every cancer has its unique set of molecular changes. Technologies have been developed to study cancers and derive molecular characteristics that increasingly have implications for clinical care. Indeed, the identification of key genetic aberrations (molecular drivers) may ultimately translate into dramatic benefit for patients through the development of highly targeted therapies. With the increasing availability of newer, more powerful, and cheaper technologies such as multiplex mutational screening, next generation sequencing, array-based approaches that can determine gene copy numbers, methylation, expression, and others, as well as more sophisticated interpretation of high-throughput molecular information using bioinformatics tools like signatures and predictive algorithms, cancers will routinely be characterized in the near future. This review examines the background information and technologies that clinicians and physicianscientists will need to interpret in order to develop better, personalized treatment strategies.
UR - http://www.scopus.com/inward/record.url?scp=79952943956&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952943956&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2011.01.013
DO - 10.1053/j.seminoncol.2011.01.013
M3 - Article
C2 - 21421108
AN - SCOPUS:79952943956
SN - 0093-7754
VL - 38
SP - 173
EP - 185
JO - Seminars in Oncology
JF - Seminars in Oncology
IS - 2
ER -